MyOme
Latest round
- Series B
Last raised
- Jun 2022
Total raised
- $23M
Investors
- 8
About MyOme
Founded in 2017 and based in California, US, MyOme Inc. is a biotech company that helps families and individuals to understand and identify genes and diseases that are inherited from their family. Founders of the company include Matthew Rabinowitz, co-founder of Natera, Kate Im, and Akash Kumar. In October 2019, MyOme Inc. at USD 132 million post-money. The company offers a complete analysis of disease risk through clinical-grade whole genome sequencing. MyOme analyzes the DNA data and provides proactive health and pharmacogenomics reports on-demand to answer clinically relevant questions throughout a patient’s life related to risk for cardiac, diabetes, autoimmune, cancer risk, and other conditions, response to certain medications, single gene and polygenic analysis to assess the risk of multifactorial diseases, rare diseases, and pharmacogenomics.
Who invested in MyOme
8 investors across 3 rounds
See all investors in MyOme
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about MyOme
Who invested in MyOme?
MyOme has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has MyOme raised?
MyOme has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did MyOme last raise money?
MyOme's most recent round on record is a Series B, in Jun 2022.
What does MyOme do?
Founded in 2017 and based in California, US, MyOme Inc.
Where is MyOme headquartered?
MyOme is headquartered in Palo Alto, US.
Which VCs invest in companies like MyOme?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at MyOme's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like MyOme? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.